Literature DB >> 9311861

Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.

M M Georgescu1, J Balanant, A Macadam, D Otelea, M Combiescu, A A Combiescu, R Crainic, F Delpeyroux.   

Abstract

Attenuated strains of the Sabin oral poliovirus vaccine replicate in the human gut and in rare cases cause vaccine-associated paralytic poliomyelitis (VAPP). Reversion of vaccine strains toward a pathogenic phenotype is probably one of the main causes of VAPP, a disease most frequently associated with type 3 and type 2 strains and more rarely with the type 1 (Sabin 1) strain. To identify the determinants and mechanisms of safety versus pathogenicity of the Sabin 1 strain, we characterized the genetic and phenotypic changes in six Sabin 1-derived viruses isolated from immunocompetent patients with VAPP. The genomes of these strains carried either few or numerous mutations from the original Sabin 1 genome. As assessed in transgenic mice carrying the human poliovirus receptor (PVR-Tg mice), all but one strain had lost the attenuated phenotype. Four strains presented only a moderate neurovirulent phenotype, probably due at least in part to reversions to the wild-type genotype, which were detected in the 5' noncoding region of the genome. The reversions found in most strains at nucleotide position 480, are known to be associated with an increase in neurovirulence. The construction and characterization of Sabin 1 mutants implicated a reversion at position 189, found in one strain, in the phenotypic change. The presence of 71 mutations in one neurovirulent strain suggests that a vaccine-derived strain can survive for a long time in humans. Surprisingly, none of the strains analyzed were as neurovirulent to PVR-Tg mice as was the wild-type parent of Sabin 1 (Mahoney) or a previously identified neurovirulent Sabin 1 mutant selected at a high temperature in cultured cells. Thus, in the human gut, the Sabin 1 strain does not necessarily evolve toward the genetic characteristics and high neuropathogenicity of its wild-type parent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311861      PMCID: PMC192128          DOI: 10.1128/JVI.71.10.7758-7768.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Investigation of five cases of vesicular enteroviral stomatitis with exanthema induced by coxsackie A5 virus.

Authors:  L Bârlean; G Avram; E Pavlov; F Cotor
Journal:  Rev Roum Virol       Date:  1994 Jan-Jun

2.  Consistent selection of mutations in the 5'-untranslated region of oral poliovirus vaccine upon passaging in vitro.

Authors:  K M Chumakov; E M Dragunsky; L P Norwood; M P Douthitt; Y Ran; R E Taffs; J Ridge; I S Levenbook
Journal:  J Med Virol       Date:  1994-01       Impact factor: 2.327

3.  Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis.

Authors:  M Furione; S Guillot; D Otelea; J Balanant; A Candrea; R Crainic
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

Review 4.  Genetics of poliovirus.

Authors:  E Wimmer; C U Hellen; X Cao
Journal:  Annu Rev Genet       Date:  1993       Impact factor: 16.830

5.  Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction.

Authors:  S Guillot; D Otelea; F Delpeyroux; R Crainic
Journal:  Vaccine       Date:  1994-05       Impact factor: 3.641

6.  Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine.

Authors:  G V Rezapkin; K M Chumakov; Z Lu; Y Ran; E M Dragunsky; I S Levenbook
Journal:  Virology       Date:  1994-07       Impact factor: 3.616

7.  A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice.

Authors:  M Tardy-Panit; B Blondel; A Martin; F Tekaia; F Horaud; F Delpeyroux
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  Mouse neurovirulence determinants of poliovirus type 1 strain LS-a map to the coding regions of capsid protein VP1 and proteinase 2Apro.

Authors:  H H Lu; C F Yang; A D Murdin; M H Klein; J J Harber; O M Kew; E Wimmer
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

9.  Precise missense and silent point mutations are fixed in the genomes of poliovirus mutants from persistently infected cells.

Authors:  S Borzakian; I Pelletier; V Calvez; F Colbere-Garapin
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

10.  Transgenic mice carrying the human poliovirus receptor: new animal models for study of poliovirus neurovirulence.

Authors:  H Horie; S Koike; T Kurata; Y Sato-Yoshida; I Ise; Y Ota; S Abe; K Hioki; H Kato; C Taya
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

View more
  29 in total

1.  Neurovirulence of type 1 polioviruses isolated from sewage in Japan.

Authors:  Hitoshi Horie; Hiromu Yoshida; Kumiko Matsuura; Miwako Miyazawa; Yoshihiro Ota; Takashi Nakayama; Yutaka Doi; So Hashizume
Journal:  Appl Environ Microbiol       Date:  2002-01       Impact factor: 4.792

2.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

3.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Membrane adsorption with direct cell culture combined with reverse transcription-PCR as a fast method for identifying enteroviruses from sewage.

Authors:  D Papaventsis; N Siafakas; P Markoulatos; G T Papageorgiou; C Kourtis; E Chatzichristou; C Economou; S Levidiotou
Journal:  Appl Environ Microbiol       Date:  2005-01       Impact factor: 4.792

6.  Detection of unusual mutation within the VP1 region of different re-isolates of poliovirus Sabin vaccine.

Authors:  Evaggelos Dedepsidis; Ioannis Karakasiliotis; Eleni Paximadi; Zaharoula Kyriakopoulou; Dimitrios Komiotis; Panayotis Markoulatos
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

7.  Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine.

Authors:  E A Cherkasova; M L Yakovenko; G V Rezapkin; E A Korotkova; O E Ivanova; T P Eremeeva; L I Krasnoproshina; N I Romanenkova; N R Rozaeva; L Sirota; V I Agol; K M Chumakov
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  Retrospective characterization of a vaccine-derived poliovirus type 1 isolate from sewage in Greece.

Authors:  Evaggelos Dedepsidis; Zaharoula Kyriakopoulou; Vaia Pliaka; Christine Kottaridi; Eugenia Bolanaki; Stamatina Levidiotou-Stefanou; Dimitri Komiotis; Panayotis Markoulatos
Journal:  Appl Environ Microbiol       Date:  2007-09-07       Impact factor: 4.792

Review 9.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

10.  Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine.

Authors:  Sabine van der Sanden; Mark A Pallansch; Jan van de Kassteele; Nasr El-Sayed; Roland W Sutter; Marion Koopmans; Harrie van der Avoort
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.